CN109232600A - 具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 - Google Patents
具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 Download PDFInfo
- Publication number
- CN109232600A CN109232600A CN201811168500.0A CN201811168500A CN109232600A CN 109232600 A CN109232600 A CN 109232600A CN 201811168500 A CN201811168500 A CN 201811168500A CN 109232600 A CN109232600 A CN 109232600A
- Authority
- CN
- China
- Prior art keywords
- radix glycyrrhizae
- methylbenzyl
- tumor activity
- preparation
- soil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002689 soil Substances 0.000 title claims abstract description 52
- 125000006178 methyl benzyl group Chemical group 0.000 title claims abstract description 47
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- 239000000375 suspending agent Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 208000019065 cervical carcinoma Diseases 0.000 claims abstract description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 41
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000012043 crude product Substances 0.000 claims description 15
- 239000007795 chemical reaction product Substances 0.000 claims description 14
- ZFXMPYNGDGXWSU-UHFFFAOYSA-N CBrCC1=CC=CC=C1 Chemical compound CBrCC1=CC=CC=C1 ZFXMPYNGDGXWSU-UHFFFAOYSA-N 0.000 claims description 12
- 239000012044 organic layer Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- -1 hydroxy-propyl Chemical group 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 7
- 201000010881 cervical cancer Diseases 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 241000252212 Danio rerio Species 0.000 description 17
- 210000001161 mammalian embryo Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- ZGFASEKBKWVCGP-UHFFFAOYSA-N cyclocoumarol Chemical compound C12=CC=CC=C2OC(=O)C2=C1OC(OC)(C)CC2C1=CC=CC=C1 ZGFASEKBKWVCGP-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- XGPBRZDOJDLKOT-UHFFFAOYSA-N praeruptorin A Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)=CC)C(C)(C)O1 XGPBRZDOJDLKOT-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- PHHAXWBLJNBVNS-UHFFFAOYSA-N Isoglycycoumarin Natural products C=1C=2C(OC)=C3CCC(C)(C)OC3=CC=2OC(=O)C=1C1=CC=C(O)C=C1O PHHAXWBLJNBVNS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000000875 Spinal Curvatures Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- CRRUGYDDEMGVDY-UHFFFAOYSA-N 1-bromoethylbenzene Chemical compound CC(Br)C1=CC=CC=C1 CRRUGYDDEMGVDY-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000448255 Congiopodus peruvianus Species 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 241000522195 Dalbergia Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- FNVCLGWRMXTDSM-WOJBJXKFSA-N Samidin Chemical compound C1=CC(=O)OC2=C3[C@@H](OC(=O)C)[C@@H](OC(=O)C=C(C)C)C(C)(C)OC3=CC=C21 FNVCLGWRMXTDSM-WOJBJXKFSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- FNVCLGWRMXTDSM-UHFFFAOYSA-N samidin Natural products C1=CC(=O)OC2=C3C(OC(=O)C)C(OC(=O)C=C(C)C)C(C)(C)OC3=CC=C21 FNVCLGWRMXTDSM-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有抗肿瘤活性的O‑对甲基苄基土甘草A,其化学结构式如下所示:
Description
技术领域
本发明涉及吡喃香豆素类化合物制备技术领域。更具体地说,本发明涉及一种具有抗 肿瘤活性的O-对甲基苄基土甘草A、制备方法、及药物制剂和用途。
背景技术
香豆素是一类存在于伞形科、豆科、菊科、芸香科等的植物,具有苯并α-吡喃酮为母 核的天然产物,其具有抗肿瘤、抗氧化、抗HIV病毒、抗凝、抗微生物等多种生物活性。 就现代学者研究的趋势来看,香豆素类化合物具有来源广、种类多、合成较简单、相对分 子质量小、生物利用度高等优点,其药理作用得到了众多学者的关注与研究,其应用与开 发有实用价值。我国的植物资源来源丰富,因此香豆素衍生物的发展空间大。壮药中两粤 黄檀Dalbergia benthami Prain,又名:蕉藤麻,两粤檀,藤本,生于灌木、疏林丛中,分 布在广西、海南、广东等地。本课题组从两粤黄檀中分离出一单体化合物,并经1HNMR、 13CNMR、MS鉴定为土甘草A,其结构归为吡喃香豆素这一类化合物,在植物中的含量 很高,达到3.5%。土甘草A(吡喃香豆素)是大环共轭体系,具刚性平面结构,具有荧 光,其化学结构式如下所示:
初步药理作用显示土甘草A对DPPA和ABTS自由基均有明显的清除作用,自由基 与很多疾病如抗炎、抗肿瘤效应的靶点有关,初步抗炎、抗肿瘤活性显示土甘草A具有较 好的活性,如何对土甘草A进行全合成或半合成,突破自然来源有限的瓶颈,为吡喃香豆 素类化合物的进一步开发利用提供依据和参考,进一步,提高土甘草A对宫颈癌Hela抑 制效果是目前急需解决的问题。
发明内容
本发明的一个目的是解决至少上述问题,并提供至少后面将说明的优点。
本发明还有一个目的是提供一种具有抗肿瘤活性的O-对甲基苄基土甘草A,其体外 抗肿瘤试验表明该化合物对宫颈癌Hela具有较强的抑制作用。
本发明还有一个目的是提供一种具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方 法,制作方法简单,且只需两步结晶即可提纯,提纯方法简便。
为了实现根据本发明的这些目的和其它优点,提供了一种具有抗肿瘤活性的O-对甲 基苄基土甘草A,其化学结构式如下所示:
提供了一种具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,包括以下步骤:
向土甘草A中加入DMF溶解后,加入碳酸钾,升温至80℃,分批加入过量的对甲基苄基溴,控制温度为60-80℃反应40-60min,得反应产物,反应产物提纯得O-对甲基苄基 土甘草A。
优选的是,土甘草A,碳酸钾、及对甲基苄基溴的摩尔比为1:0.1:2-10。
优选的是,土甘草A,及DMF的质量比为1:5-10。
优选的是,反应产物提纯的方法具体为:将反应产物冷却至室温,加水至沉淀析出完 全,过滤得沉淀结晶,沉淀结晶用二氯甲烷萃取3次取有机层,并将有机层水洗3次后无水硫酸钠干燥至少12h,蒸干溶剂后得粗产物,粗产物重结晶后过滤即可,其中,粗产物 重结晶所用溶剂为无水乙醇、乙腈、乙酸乙酯中的一种。
提供了一种具有抗肿瘤活性的O-对甲基苄基土甘草A的药物制剂,其特征在于,所述药物制剂为由O-对甲基苄基土甘草A及药学上可接受的辅料制成。
优选的是,具有抗肿瘤活性的O-对甲基苄基土甘草A的药物制剂为注射剂、片剂、丸剂、胶囊、悬浮剂或乳剂。
优选的是,药学上可接受的辅料为乙醇、丙二醇、聚乙二醇、二甘醇、三乙酸甘油酯、 甘油、糊精、聚维酮、十八醇、硬脂酸、微晶纤维素、淀粉、乳糖、甘露醇、碳酸氢钠、 碳酸钙、低取代羟丙基甲基纤维素、硬脂酸镁、滑石粉中的一种或几种。
提供了一种具有抗肿瘤活性的O-对甲基苄基土甘草A的用途,所述的O-对甲基苄基 土甘草A在制备治疗宫颈癌的药物中的应用。
本发明至少包括以下有益效果:
第一、O-对甲基苄基土甘草A对肿瘤细胞株的抑制率达到72%,相对于土甘草A的10%有显著的提高,
第二、O-对甲基苄基土甘草A的制备方法,制作方法简单,且只需两步结晶即可提纯,提纯方法简便。
第三、O-对甲基苄基土甘草A配合药学上可接受的辅料可制成注射剂、片剂、丸剂、胶囊、悬浮剂或乳剂多种剂型,适应广大患者用药需求。
本发明的其它优点、目标和特征将部分通过下面的说明体现,部分还将通过对本发明 的研究和实践而为本领域的技术人员所理解。
具体实施方式
下面结合实施例对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字 能够据以实施。
<实施例1>
具有抗肿瘤活性的O-对甲基苄基土甘草A,其化学结构式如下所示:
具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,包括以下步骤:
向土甘草A中加入其重量5倍量的DMF溶解后,加入碳酸钾,升温至80℃,分两批 等量加入对甲基苄基溴(两次加入对甲基苄基溴的间隔时间为10min),控制温度为60-80℃之间,反应50min,得反应产物,将反应产物冷却至室温,加水至沉淀析出完全,过滤得 沉淀结晶,沉淀结晶用二氯甲烷萃取3次取有机层,并将有机层水洗3次后无水硫酸钠干 燥14h,蒸干溶剂后得粗产物,粗产物重结晶后过滤得O-对甲基苄基土甘草A,其中,土 甘草A,碳酸钾、及对甲基苄基溴的摩尔比为1:0.1:2,粗产物重结晶所用溶剂为无水乙醇。
制得的O-对甲基苄基土甘草A的为淡黄色固体,产率28.45%,m.p.211.5-213.8℃; FAB-MS m/z::485.66([M+H]+);
核磁共振氢谱数据:1HNMR(CDCl3,600MHz)δ:7.5(d,J=12Hz,2H,ArH), 7.1(d,J=12Hz,2H,ArH),6.9(d,J=6Hz,4H,ArH),6.6(t,J=6Hz,J=6Hz,2H, ArH),5.7(d,J=12Hz,H,ArH),4.65(d,J=30Hz,2H,-O-CH2-),3.89(s,3H,-OCH3), 3.7(s,3H,-OCH3),2.3(d,J=6Hz,3H,-CH3),1.51(s,6H,-CH3);
核磁共振碳谱数据:13CNMR(CDCl3,150Hz)δ:163.27,162.84,159.33,157.07,154.98,152.91,147.37,138.10,132.14,129.02,128.91,125.31,124.76,124.04,116.07,113.65,112.90,112.85,111.41,108.09,105.52,105.39,101.07,99.78,77.52,77.03,76.77,73.03,63.57,55.36。
<实施例2>
具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,包括以下步骤:
向土甘草A中加入其重量8倍量的DMF溶解后,加入碳酸钾,升温至80℃,分三批 等量加入对甲基苄基溴(相邻两次加入对甲基苄基溴的间隔时间为6min),控制温度为 60-80℃之间反应40min,得反应产物,将反应产物冷却至室温,加水至沉淀析出完全,过 滤得沉淀结晶,沉淀结晶用二氯甲烷萃取3次取有机层,并将有机层水洗3次后无水硫酸 钠干燥15h,蒸干溶剂后得粗产物,粗产物重结晶后过滤得O-对甲基苄基土甘草A,其中, 土甘草A,碳酸钾、及对甲基苄基溴的摩尔比为1:0.1:6,粗产物重结晶所用溶剂为乙腈。
制得的O-对甲基苄基土甘草A的为淡黄色固体,产率32.85%。
<实施例3>
具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,包括以下步骤:
向土甘草A中加入其重量10倍量的DMF溶解后,加入碳酸钾,升温至80℃,分两 批等量加入对甲基苄基溴(两次加入对甲基苄基溴的间隔时间为10min),控制温度为 60-80℃之间反应60min,得反应产物,将反应产物冷却至室温,加水至沉淀析出完全,过 滤得沉淀结晶,沉淀结晶用二氯甲烷萃取3次取有机层,并将有机层水洗3次后无水硫酸 钠干燥12h,蒸干溶剂后得粗产物,粗产物重结晶后过滤得O-对甲基苄基土甘草A,其中, 土甘草A,碳酸钾、及对甲基苄基溴的摩尔比为1:0.1:10,粗产物重结晶所用溶剂为无水 乙酸乙酯。
制得的O-对甲基苄基土甘草A的为淡黄色固体,产率34.15%。
<实施例4>
药物制剂,具体如表1所示:
表1
1、体外抗肿瘤活性实验
以实施例1制备的O-对甲基苄基土甘草A、及土甘草A作为待测化合物,分别采用MTS法进行体外抗肿瘤筛选,具体步骤为:
①接种细胞:用含10%胎牛血清的培养液(DMEM)配成单个细胞悬液,以每孔3000~15000个细胞接种到96孔板,每孔体积100μl,细胞提前12~24小时接种培养;
②加入待测化合物溶液:用DMSO分别溶解待测化合物,设置待测化合物的初始浓度80μM,分别对宫颈癌Hela肿瘤细胞进行初筛,每孔终体积为200μl,每种处理均设3 个复孔;
③显色:37摄氏度培养48小时后,贴壁细胞弃孔内培养液,每孔加MTS溶液20μl 和培养液100μl,同步设3个空白复孔(MTS溶液20μl和培养液100μl的混合液),继续 孵育2~4小时,使反应充分进行后测定光吸收值;
④比色:选择492nm波长,多功能酶标仪(MULTISKAN FC)读取各孔光吸收值, 记录结果并处理得对应待测化合物对宫颈癌Hela肿瘤细胞的抑制率,如表2所示:
表2 O-对甲基苄基土甘草A对肿瘤细胞株的抑制率(%)
宫颈癌Hela | |
O-对甲基苄基土甘草A | 72% |
土甘草A | 10% |
从表2的结果可以看出,本发明的O-对甲基苄基土甘草A经体外抗肿瘤实验表明,该化合物对宫颈癌Hela肿瘤细胞具有较高的抑制率,即该化合物具有强的抗肿瘤活性。 本发明为研究开发新的土甘草A药物提供了新的思路。
2、斑马鱼毒性检测实验
2.1实验材料:
选取由南方医科大学斑马鱼实验中心提供的野生型AB系雄性斑马鱼,养鱼系统为北 京爱生公司净水系统,制系统温度在28.5-29.5℃,盐浓度为0.03%-0.04%,pH为7.2-7.6, 昼夜光照控制14h光照,具体时间为8:30am-10:30pro),10h黑夜;
斑马鱼培养液参照Zebrafish Book标准配制(0.137moL/L NaCl,5.4mmoL/L KCl,0.25mmoL/L Na2HPO4,0.44mmoL/L KH2PO4,1.3mmoL/L CaCl2,1.0mmoL/L MgSO4, 4.2mmoL/LNaHCO3)。
2.2药液的配制
土甘草A用二甲亚砜(DMSO)助溶,分别配成浓度为2.0mg/mL、1.5mg/mL、1mg/mL 的药液,避光置于-20℃冰箱保存;
实施例1制备的O-对甲基苄基土甘草A用二甲亚砜(DMSO)助溶,分别配成浓度 为2.0mg/mL、1.5mg/mL、1mg/mL的药液,避光置于-20℃冰箱保存。
2.3胚胎的处理方法
在正置显微镜下挑选正常发育6h(6hpf)的斑马鱼胚胎,随机移入6孔板的样孔中,每孔20枚;
取各浓度药液100μL及斑马鱼培养液加入各样孔中,使每孔所含DMSO终浓度为2%,并设纯孵化液组(对照组)及含2%DMSO的孵化液组。药物暴露72h,为尽量减 少实验误差,以上实验每个重复3遍,所用胚胎为同一批受精胚胎;
将斑马鱼胚胎分别置于6孔板且以1%-5%的DMSO以5个浓度梯度(1%、2%、3%、4%、5%)孵育斑马鱼胚胎,每组胚胎20个,每组实验重复3次。主要观测不同浓度DMSO 对斑马鱼胚胎造成的死亡或畸形的发生率;
2.4数据处理
采用概率单位法分析斑马鱼胚胎在不同药物浓度,药物暴露72h后,各系列代表药物的死亡率及致畸率;用SPSS 13.0卡方检验对各组间死亡率和畸形率进行比较,P<0.05时,有统计学意义。
2.5结果与讨论
斑马鱼胚胎的观察的指标有:
Ⅰ类指标(致死性指标):卵凝结,无心跳,不孵化;
Ⅱ类指标(揭示受试药物特定的作用方式的非致死性指标):无血液循环,发育畸形、 孵化延迟;
在对各浓度DMSO对斑马鱼影响实验中发现,1%、2%DMSO对斑马鱼胚胎影响不大。但当浓度达到3%以上时,胚胎发育出膜受到极大影响,脊柱弯曲严重,5%DMSO在48hpf 时全部胚胎无出膜,甚至有腐烂趋势。鉴于目标产物水溶性较差,1%DMSO仍出现沉淀, 因此本实验采用2%DMSO溶解目标产物。选取72hpf各系列代表药物斑马鱼胚胎(72hpf) 畸形率和死亡率进行统计。
表3斑马鱼胚胎(72hpf)畸形率和死亡率比较(n=20)
由表3可知,各化合物在不同的浓度下均出现了不同程度的畸形,如不孵化、卵凝结、 脊柱弯曲、心包肿大,胚胎的死亡率和畸形率总和随着各化合物浓度的增加而增大,呈现 出量效关系,纯孵化液组及2%DMSO的孵化液组组胚胎发育正常,按时出膜,土甘草A 普遍表现出了较强的毒性,化合物2.0mg/L组中,对斑马鱼的死亡率和畸形率总和达到100%,死亡率达到了45%,表现出很强的胚胎毒性,O-对甲基苄基土甘草A对斑马鱼的 死亡率和畸形率低于土甘草A。含药实验组与对照组相比,死亡率和畸形率差异均有统计 学意义(P<0.01)。
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运 用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地 实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限 于特定的细节和这里示出与描述的实施例。
Claims (9)
1.具有抗肿瘤活性的O-对甲基苄基土甘草A,其特征在于,其化学结构式如下所示:
2.如权利要求1所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,其特征在于,包括以下步骤:
向土甘草A中加入DMF溶解后,加入碳酸钾,升温至80℃,分批加入过量的对甲基苄基溴,控制温度为60-80℃反应40-60min,得反应产物,反应产物提纯得O-对甲基苄基土甘草A。
3.如权利要求2所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,其特征在于,土甘草A,碳酸钾、及对甲基苄基溴的摩尔比为1:0.1:2-10。
4.如权利要求2所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,其特征在于,土甘草A,及DMF的质量比为1:5-10。
5.如权利要求2所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的制备方法,其特征在于,反应产物提纯的方法具体为:将反应产物冷却至室温,加水至沉淀析出完全,过滤得沉淀结晶,沉淀结晶用二氯甲烷萃取3次取有机层,并将有机层水洗3次后无水硫酸钠干燥至少12h,蒸干溶剂后得粗产物,粗产物重结晶后过滤即可,其中,粗产物重结晶所用溶剂为无水乙醇、乙腈、乙酸乙酯中的一种。
6.如权利要求1所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的药物制剂,其特征在于,所述药物制剂为由O-对甲基苄基土甘草A及药学上可接受的辅料制成。
7.如权利要求6所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的药物制剂,其特征在于,其为注射剂、片剂、丸剂、胶囊、悬浮剂或乳剂。
8.如权利要求6所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的药物制剂,其特征在于,药学上可接受的辅料为乙醇、丙二醇、聚乙二醇、二甘醇、三乙酸甘油酯、甘油、糊精、聚维酮、十八醇、硬脂酸、微晶纤维素、淀粉、乳糖、甘露醇、碳酸氢钠、碳酸钙、低取代羟丙基甲基纤维素、硬脂酸镁、滑石粉中的一种或几种。
9.如权利要求1所述的具有抗肿瘤活性的O-对甲基苄基土甘草A的用途,其特征在于,所述的O-对甲基苄基土甘草A在制备治疗宫颈癌的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811168500.0A CN109232600B (zh) | 2018-10-08 | 2018-10-08 | 具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811168500.0A CN109232600B (zh) | 2018-10-08 | 2018-10-08 | 具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109232600A true CN109232600A (zh) | 2019-01-18 |
CN109232600B CN109232600B (zh) | 2021-04-20 |
Family
ID=65055331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811168500.0A Expired - Fee Related CN109232600B (zh) | 2018-10-08 | 2018-10-08 | 具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109232600B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216176A (en) * | 1989-01-23 | 1993-06-01 | Lehigh University | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor |
CN1425667A (zh) * | 2001-12-12 | 2003-06-25 | 方宏勋 | 一种具有抗肿瘤作用的新化合物、其制备方法及在制备治疗肿瘤药物中的应用 |
WO2008102994A1 (en) * | 2007-02-22 | 2008-08-28 | Yong Jin Park | Composition comprising decursin derivative for treating and preventing atopic dermatitis |
CN103319497A (zh) * | 2012-03-22 | 2013-09-25 | 巴塞利亚药业(中国)有限公司 | 天然产物Hirtellanine B及其衍生物的制备方法与在制备治疗肿瘤药物中的应用 |
CN104341430A (zh) * | 2014-09-30 | 2015-02-11 | 广西中医药大学 | 一种土甘草a及其提取方法和用途 |
CN104945408A (zh) * | 2015-04-30 | 2015-09-30 | 广西民族大学 | 香豆素类化合物及其制备方法和应用 |
-
2018
- 2018-10-08 CN CN201811168500.0A patent/CN109232600B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216176A (en) * | 1989-01-23 | 1993-06-01 | Lehigh University | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor |
CN1425667A (zh) * | 2001-12-12 | 2003-06-25 | 方宏勋 | 一种具有抗肿瘤作用的新化合物、其制备方法及在制备治疗肿瘤药物中的应用 |
WO2008102994A1 (en) * | 2007-02-22 | 2008-08-28 | Yong Jin Park | Composition comprising decursin derivative for treating and preventing atopic dermatitis |
CN103319497A (zh) * | 2012-03-22 | 2013-09-25 | 巴塞利亚药业(中国)有限公司 | 天然产物Hirtellanine B及其衍生物的制备方法与在制备治疗肿瘤药物中的应用 |
CN104341430A (zh) * | 2014-09-30 | 2015-02-11 | 广西中医药大学 | 一种土甘草a及其提取方法和用途 |
CN104945408A (zh) * | 2015-04-30 | 2015-09-30 | 广西民族大学 | 香豆素类化合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109232600B (zh) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105198885B (zh) | 具有抗心律失调活性的化合物communesin I及其制备方法和用途 | |
CN109438461B (zh) | 具有抗白血病活性的土甘草a衍生物及其制备方法和用途 | |
CN109232601A (zh) | 具有抗宫颈癌活性的土甘草a衍生物及其制备方法和用途 | |
CN104016957A (zh) | 7-甲基-3-香叶基黄酮和7-甲基-3-异戊烯基黄酮及其制备方法和应用 | |
CN109438462B (zh) | 具有抗肿瘤活性的o-对硝基苯甲酰基土甘草a及其制备方法和用途 | |
CN109232600A (zh) | 具有抗肿瘤活性的o-对甲基苄基土甘草a、制备方法、及药物制剂和用途 | |
CN100381434C (zh) | 具有抗癌、抗菌作用的余甘子提取物的中药制剂的生产方法 | |
CN102617521B (zh) | 具有抗肿瘤活性的γ-丁内酯聚酮类化合物 | |
CN111217825B (zh) | 4-o-氨丙基土甘草a衍生物及其制备及应用 | |
US20240051914A1 (en) | The hexadecane tromethamine compound, its synthesis method and its application in antitumor and antifungal aspects | |
CN109438463B (zh) | 具有抗肿瘤活性的o-(4-溴-2-氟苯甲酰基)土甘草a、及制备方法和用途 | |
CN101747277B (zh) | 一种吲唑化合物的用途及制备 | |
CN105198714B (zh) | 杨梅醇衍生物及其制备方法和应用 | |
CN104107199A (zh) | 骆驼蓬总生物碱的制备方法 | |
CN101143861B (zh) | 一类b环4’-单取代黄酮化合物在制备抗柯萨奇b病毒感染的药物中的用途 | |
CN106883282B (zh) | 救必应酸衍生物在制备抗肿瘤的药物中的应用 | |
CN106674180B (zh) | 一种槲皮素衍生物及其制备方法和应用 | |
CN109232599B (zh) | 具有抗肿瘤活性的o-对三氟甲基苯甲酰基土甘草a及其制备方法和用途 | |
CN102260214A (zh) | 一种吲唑化合物的制备方法 | |
CN100438867C (zh) | 一种黄酮单体在制备抗病毒药物中的应用 | |
CN101857591A (zh) | 盐酸噻加宾晶型及其制备方法 | |
CN110075164A (zh) | 桂花种子提取物的制备方法、桂花种子提取物及其应用 | |
CN102838645B (zh) | 一种具有药物用途的多酚羟基黄酮化合物及其制备方法 | |
CN111925347B (zh) | 从灰枝紫菀中分离的二萜苷类化合物、制备及其保肝用途 | |
CN103880793B (zh) | 含呋喃亚胺类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210420 |